Changes in glucose and fat metabolism in response to the administration of a hepato-preferential insulin analog

Diabetes

Volumn 63, Issue 11, 2014, Pages 3946-3954

  Edgerton, Dale S ^a   Moore, Mary C ^a   Winnick, Jason J ^a   Scott, Melanie ^a   Farmer, Ben ^a   Naver, Helle ^b   Jeppesen, Claus B ^b   Madsen, Peter ^b   Kjeldsen, Thomas B ^b   Nishimura, Erica ^b   Brand, Christian L ^b   Cherrington, Alan D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; INSULIN 327; INSULIN DERIVATIVE; RECOMBINANT HUMAN INSULIN; SOMATOSTATIN; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; INSULIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; INTRAPORTAL DRUG ADMINISTRATION; LIPID METABOLISM; LIPOLYSIS; LIVER; MALE; NONHUMAN; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; METABOLISM;

ANIMALS; BLOOD GLUCOSE; DOGS; FEMALE; GLUCAGON; GLUCOSE; INSULIN; LIPID METABOLISM; LIPOLYSIS; MALE;

EID: 84908636883     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0266     Document Type: Article

References (60)

1. Greco AV, Crucitti F, Ghirlanda G, et al. Insulin and glucagon concentrations in portal and peripheral veins in patients with hepatic cirrhosis. Diabetologia 1979;17:23-28
2. Horwitz DL, Starr JI, Mako ME, Blackard WG, Rubenstein AH. Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. J Clin Invest 1975;55:1278-1283
3. Song SH, McIntyre SS, Shah H, Veldhuis JD, Hayes PC, Butler PC. Direct measurement of pulsatile insulin secretion from the portal vein in human subjects. J Clin Endocrinol Metab 2000;85:4491-4499
4. Sindelar DK, Balcom JH, Chu CA, Neal DW, Cherrington AD. A comparison of the effects of selective increases in peripheral or portal insulin on hepatic glucose production in the conscious dog. Diabetes 1996;45:1594-1604
5. Sindelar DK, Chu CA, Neal DW, Cherrington AD. Interaction of equal increments in arterial and portal vein insulin on hepatic glucose production in the dog. Am J Physiol 1997;273:E972-E980
6. Sindelar DK, Chu CA, Rohlie M, Neal DW, Swift LL, Cherrington AD. The role of fatty acids in mediating the effects of peripheral insulin on hepatic glucose production in the conscious dog. Diabetes 1997;46:187-196
7. Sindelar DK, Chu CA, Venson P, Donahue EP, Neal DW, Cherrington AD. Basal hepatic glucose production is regulated by the portal vein insulin concentration. Diabetes 1998;47:523-529
8. Chu CA, Fujimoto Y, Igawa K, et al. Rapid translocation of hepatic glucokinase in response to intraduodenal glucose infusion and changes in plasma glucose and insulin in conscious rats. Am J Physiol Gastrointest Liver Physiol 2004;286:G627-G634
9. Herring R, Jones RH, Russell-Jones DL. Hepatoselectivity and the evolution of insulin. Diabetes Obes Metab 2014;16:1-8
10. Cao W, Liu HY, Hong T, Liu Z. Excess exposure to insulin may be the primary cause of insulin resistance. Am J Physiol Endocrinol Metab 2010;298: E372
11. Hall JE, Brands MW, Zappe DH, Alonso Galicia M. Insulin resistance, hyperinsulinemia, and hypertension: causes, consequences, or merely correlations? Proc Soc Exp Biol Med 1995;208:317-329
12. Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care 2008; 31(Suppl. 2):S262-S268
13. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001;86:713-718
14. Sowers JR, Sowers PS, Peuler JD. Role of insulin resistance and hyperinsulinemia in development of hypertension and atherosclerosis. J Lab Clin Med 1994;123:647-652
15. Larger E. Weight gain and insulin treatment. Diabetes Metab 2005;31(4 Pt 2):4S51-4S56
16. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes- causes, effects and coping strategies. Diabetes Obes Metab 2007;9:799-812
17. Sallé A, Ryan M, Guilloteau G, Bouhanick B, Berrut G, Ritz P. 'Glucose control-related' and 'non-glucose control-related' effects of insulin on weight gain in newly insulin-treated type 2 diabetic patients. Br J Nutr 2005;94:931-937
18. Stout RW. Insulin and atheroma. 20-yr perspective. Diabetes Care 1990;13: 631-654
19. Bagdade JD, Teuscher AU, Ritter MC, Eckel RH, Robertson RP. Alterations in cholesteryl ester transfer, lipoprotein lipase, and lipoprotein composition after combined pancreas-kidney transplantation. Diabetes 1998;47:113-118
20. Carpentier A, Patterson BW, Uffelman KD, et al. The effect of systemic versus portal insulin delivery in pancreas transplantation on insulin action and VLDL metabolism. Diabetes 2001;50:1402-1413
21. Conway B, Costacou T, Orchard T. Is glycaemia or insulin dose the stronger risk factor for coronary artery disease in type 1 diabetes? Diab Vasc Dis Res 2009;6:223-230
22. Falholt K, Cutfield R, Alejandro R, Heding L, Mintz D. The effects of hyperinsulinemia on arterial wall and peripheral muscle metabolism in dogs. Metabolism 1985;34:1146-1149
23. Hirai FE, Moss SE, Klein BE, Klein R. Relationship of glycemic control, exogenous insulin, and C-peptide levels to ischemic heart disease mortality over a 16-year period in people with older-onset diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR). Diabetes Care 2008;31: 493-497
24. Karamitsos DT. Antiatheromatic effects of insulin. Diabetes Res Clin Pract 2011;93(Suppl. 1):S105-S108
25. Kronmal RA, Barzilay JI, Tracy RP, Savage PJ, Orchard TJ, Burke GL. The relationship of fasting serum radioimmune insulin levels to incident coronary heart disease in an insulin-treated diabetic cohort. J Clin Endocrinol Metab 2004; 89:2852-2858
26. Muis MJ, Bots ML, Bilo HJ, et al. High cumulative insulin exposure: a risk factor of atherosclerosis in type 1 diabetes? Atherosclerosis 2005;181:185-192
27. Raz I. Exogenous hyperinsulinemia and atherosclerosis in type 1 diabetic patients. J Diabetes Complications 2013;27:2-3
28. Stout RW. Hyperinsulinemia and atherosclerosis. Diabetes 1996;45(Suppl. 3):S45-S46
29. Tseng CH. Exogenous insulin use and hypertension in adult patients with type 2 diabetes mellitus. Arch Intern Med 2006;166:1184-1189
30. Edgerton DS, Lautz M, Scott M, et al. Insulin's direct effects on the liver dominate the control of hepatic glucose production. J Clin Invest 2006;116:521-527
31. Frystyk J, Ritzel RA, Maubach J, et al. Comparison of pancreastransplanted type 1 diabetic patients with portal-venous versus systemic-venous graft drainage: impact on glucose regulatory hormones and the growth hormone/insulin-like growth factor-I axis. J Clin Endocrinol Metab 2008;93:1758-1766
32. Hanaire-Broutin H, Sallerin-Caute B, Poncet MF, et al. Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM. Diabetologia 1996;39: 1498-1504
33. Duckworth WC, Saudek CD, Giobbie-Hurder A, et al. The Veterans Affairs Implantable Insulin Pump Study: effect on cardiovascular risk factors. Diabetes Care 1998;21:1596-1602
34. Liebl A, Hoogma R, Renard E, et al.; European DiaPort Study Group. A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion. Diabetes Obes Metab 2009;11:1001-1008
35. Monti LD, Piatti PM, Home PD, Tomson C, Alberti KG. The effect of intraperitoneal insulin delivery on carbohydrate metabolism in type 1 (insulindependent) diabetic patients. Diabetes Res Clin Pract 1992;15:237-244
36. Pinget M, Jeandidier N. Long term safety and efficacy of intraperitoneal insulin infusion by means of implantable pumps. Horm Metab Res 1998;30:475-486
37. Robert JJ, Chauvet D, Darmaun D, Leblanc H. Hepatic glucose production during intraperitoneal and intravenous closed-loop insulin regulation of blood glucose in type 1 (insulin-dependent) diabetic patients. Diabetologia 1993;36: 1185-1190
38. Saudek CD, Duckworth WC, Giobbie-Hurder A, et al.; Department of Veterans Affairs Implantable Insulin Pump Study Group. Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. JAMA 1996;276:1322-1327
39. Saudek CD, Selam JL, Pitt HA, et al. A preliminary trial of the programmable implantable medication system for insulin delivery. N Engl J Med 1989;321:574-579
40. Selam JL, Raccah D, Jean-Didier N, Lozano JL, Waxman K, Charles MA. Randomized comparison of metabolic control achieved by intraperitoneal insulin infusion with implantable pumps versus intensive subcutaneous insulin therapy in type I diabetic patients. Diabetes Care 1992;15:53-58
41. Shishko PI, Kovalev PA, Goncharov VG, Zajarny IU. Comparison of peripheral and portal (via the umbilical vein) routes of insulin infusion in IDDM patients. Diabetes 1992;41:1042-1049
42. Iyer H, Khedkar A, Verma M. Oral insulin - a review of current status. Diabetes Obes Metab 2010;12:179-185
43. Moore MC, Smith MS, Sinha VP, et al. Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes 2014;63:494-504
44. Shojaee-Moradie F, Powrie JK, Sundermann E, et al. Novel hepatoselective insulin analog: studies with a covalently linked thyroxyl-insulin complex in humans. Diabetes Care 2000;23:1124-1129
45. Edgerton DS, Cardin S, Emshwiller M, et al. Small increases in insulin inhibit hepatic glucose production solely caused by an effect on glycogen metabolism. Diabetes 2001;50:1872-1882
46. Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004;21: 1498-1504
47. Cowan JS, Hetenyi G Jr. Glucoregulatory responses in normal and diabetic dogs recorded by a new tracer method. Metabolism 1971;20:360-372
48. Steele R, Wall JS, De Bodo RC, Altszuler N. Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 1956;187:15-24
49. Hsieh PS, Moore MC, Neal DW, Emshwiller M, Cherrington AD. Rapid reversal of the effects of the portal signal under hyperinsulinemic conditions in the conscious dog. Am J Physiol 1999;276:E930-E937
50. Pagliassotti MJ, Holste LC, Moore MC, Neal DW, Cherrington AD. Comparison of the time courses of insulin and the portal signal on hepatic glucose and glycogen metabolism in the conscious dog. J Clin Invest 1996;97:81-91
51. Mari A, Stojanovska L, Proietto J, Thorburn AW. A circulatory model for calculating non-steady-state glucose fluxes. Validation and comparison with compartmental models. Comput Methods Programs Biomed 2003;71:269-281
52. Pagliassotti MJ, Moore MC, Neal DW, Cherrington AD. Insulin is required for the liver to respond to intraportal glucose delivery in the conscious dog. Diabetes 1992;41:1247-1256
53. Bazerbachi F, Selzner M, Marquez MA, et al. Portal venous versus systemic venous drainage of pancreas grafts: impact on long-term results. Am J Transplant 2012;12:226-232
54. Kryshak EJ, Butler PC, Marsh C, et al. Pattern of postprandial carbohydrate metabolism and effects of portal and peripheral insulin delivery. Diabetes 1990; 39:142-148
55. Petruzzo P, Badet L, Lefrançois N, et al. Metabolic consequences of pancreatic systemic or portal venous drainage in simultaneous pancreas-kidney transplant recipients. Diabet Med 2006;23:654-659
56. Young CJ. Are there still roles for exocrine bladder drainage and portal venous drainage for pancreatic allografts? Curr Opin Organ Transplant 2009;14:90-94
57. Fanelli C, Calderone S, Epifano L, et al. Demonstration of a critical role for free fatty acids in mediating counterregulatory stimulation of gluconeogenesis and suppression of glucose utilization in humans. J Clin Invest 1993;92:1617-1622
58. Edgerton DS, Ramnanan CJ, Grueter CA, et al. Effects of insulin on the metabolic control of hepatic gluconeogenesis in vivo. Diabetes 2009;58:2766-2775
59. Flakoll PJ, Jensen MD, Cherrington AD. Physiologic action of insulin. In Diabetes Mellitus: A Fundamental and Clinical Text, 3rd ed. LeRoith D, Taylor SI, Olefsky JM, eds. Philadelphia, Lippincott Williams & Wilkins, 2004, p. 165-181
60. Smeeton F, Shojaee Moradie F, Jones RH, et al. Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes. Diabetologia 2009;52:2317-2323